Skip to main content

Press Releases

February 12, 2019

BERKELEY, CA – February 12, 2019 – Caribou Biosciences, Inc., a leading CRISPR genome editing company, announced today that it has expanded its Scientific Advisory Board (SAB) with the appointment of six new members: Emily Balskus, PhD; Ami Bhatt, MD, PhD; Dean Lee, MD, PhD; Jeffrey Rathmell, PhD; Noopur Raje, MD; and Cameron Turtle, MBBS, PhD. The newly appointed members will work with current SAB members and Caribou co-founders Jennifer Doudna, PhD and Martin Jinek, PhD.

December 12, 2018

BERKELEY, CA – December 12, 2018 – Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Natalie Sacks, MD to its Board of Directors. Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics. 

In the News

This Scientist Turned CEO Wants to Gene-Edit a Way to Cure Cancer

March 16, 2018

In a fashionable fitted blazer, Rachel Haurwitz looks the part of a polished executive when she meets me in the largest conference room of her company, Caribou Biosciences. She’s sharp and tactical as she speaks, even though it was just a few years ago that Haurwitz traded her lab coat for a tailored suit and stepped up to lead a staff of 46 as Caribou’s CEO.

Diverse Perspectives — Insights for 2018 From Biopharma's Leading Women

November 30, 2017

When recruiting for last year’s executive outlook article, What 13 Life Science Trendsetters Expect For 2017 And Beyond, I made a concerted effort to have diversity well represented. And while we succeeded in getting a wide cross section of diverse opinions from very different organizations, I failed when it came to having female life science leaders well represented. This year Life Science Leader had 12 CEOs agree to participate (the highest number of CEOs to ever take part in this article), and five of these are women.

About Us

Pioneering the translation of CRISPR-Cas genome engineering into new medical therapies and bio-based products. Learn more. 

Contact Us

For media and investor inquiries and general information, click here.

Follow Us

Connect with us on Twitter for the latest news and updates. Click here.

Media Contact

Greg Kelley
Senior Vice President
Feinstein Kean Healthcare
(404) 836-2302